drugset
Drugs / Lexgenleucel-T
last change Dec 2013 re-read 3 minutes ago

Lexgenleucel-T

also known as VRX496 · VRX496-T

Cell therapy

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · University of Pennsylvania

Trials 1

today NCT00295477 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00295477 Jan 2006 → Apr 2010 HIV infectious disease University of Pennsylvania Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lexgenleucel-T “We report the safety and tolerability of 87 infusions of lentiviral vector–modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with...” PMID 23264589 ↗ Dec 2012
Known as VRX496 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00295477 ↗
Known as VRX496-T “We report the safety and tolerability of 87 infusions of lentiviral vector–modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with...” PMID 23264589 ↗ Dec 2012
Modality Cell therapy — CHEMBL2107847 ↗